Sharp Clinical Seeks Approval to Import Controlled Drugs

2026-06523 — Designation of P2P Methyl Glycidic Acid as a List I Chemical

Starting May 4, 2026, anyone handling P2P methyl glycidic acid—a key chemical used to make illegal drugs like methamphetamine—must follow new government rules and register with the DEA. This means all transactions, big or small, will be closely watched to stop illegal drug production. Businesses dealing with this chemical should act fast to stay legal and avoid penalties.

2026-06521 — Importer of Controlled Substances Application: Lipomed/LGC Standards

Lipomed/LGC Standards wants to become an official importer of certain controlled substances, like 3-Fluoro-N-methylcathinone. This means companies involved with these drugs can comment or ask for a hearing by May 4, 2026. If approved, it could impact how these substances enter the U.S., but no direct costs are mentioned yet.

2026-06051 — Importer of Controlled Substances Application: Usona Institute

Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.

2026-05912 — Bulk Manufacturer of Controlled Substances Application: SpecGx LLC

SpecGx LLC wants to become a big-time maker of some powerful and tightly controlled drugs, including things like psilocybin and fentanyl. People and companies already registered can share their thoughts or ask for a hearing by May 26, 2026. This move could shake up how these substances are made and handled, so keep an eye on the deadlines if you’re involved!

2026-05618 — Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I

Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.

2026-05486 — Exempt Chemical Preparations Under the Controlled Substances Act

The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!

Previous: 2025-03025 — Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing of a Proposed Rule Change To List and Trade Shares of the WisdomTree XRP Fund Under BZX Rule 14.11(e)(4), Commodity-Based Trust Shares

Cboe BZX Exchange wants to start listing and trading shares of the new WisdomTree XRP Fund, which is tied to the cryptocurrency XRP. This change lets investors buy and sell these shares on the exchange, opening up fresh opportunities in crypto investing. The proposal was filed in early February 2025 and is now open for public comments before it goes live.

Next: 2025-03061 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC

Catalent Pharma Solutions, LLC wants to officially import certain controlled substances. This means they’re asking the government’s permission to bring in these special drugs safely and legally. If approved, it could affect companies and patients relying on these medicines, with no immediate cost changes announced.